Andersons pediatric cardiology 2122
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (60.67 KB, 3 trang )
90.WrenC,CampbellRW.Theresponseof
paediatricarrhythmiastointravenousandoral
flecainide.BrHeartJ.1987;57(2):171–175.
91.BernsE,RinkenbergerRL,JeangMK,etal.
Efficacyandsafetyofflecainideacetatefor
atrialtachycardiaorfibrillation.AmJCardiol.
1987;59(15):1337–1341.
92.AndersonJL,StewartJR,PerryBA,etal.Oral
flecainideacetateforthetreatmentofventricular
arrhythmias.NEnglJMed.1981;305(9):473–
477.
93.PerryJC,GarsonAJr.Flecainideacetatefor
treatmentoftachyarrhythmiasinchildren:
reviewofworldliteratureonefficacy,safety,and
dosing.AmHeartJ.1992;124(6):1614–1621.
94.PerryJC,McQuinnRL,SmithRTJr,etal.
Flecainideacetateforresistantarrhythmiasin
theyoung:efficacyandpharmacokinetics.JAm
CollCardiol.1989;14(1):185–191[discussion
192–193].
95.AliotE,CapucciA,CrijnsHJ,GoetteA,
TamargoJ.Twenty-fiveyearsinthemaking:
flecainideissafeandeffectiveforthe
managementofatrialfibrillation.Europace.
2011;13(2):161–173.
96.McQuinnRL,QuarfothGJ,JohnsonJD,etal.
Biotransformationandeliminationof14c-
flecainideacetateinhumans.DrugMetab
Dispos.1984;12(4):414–420.
97.ConardGJ,OberRE.Metabolismofflecainide.
AmJCardiol.1984;53(5):41B–51B.
98.ConardGJ,CarlsonGL,FrostJW,etal.Plasma
concentrationsofflecainideacetate,anew
antiarrhythmicagent,inhumans.ClinTher.
1984;6(5):643–652.
99.MikusG,GrossAS,BeckmannJ,etal.The
influenceofthesparteine/debrisoquinphenotype
onthedispositionofflecainide.ClinPharmacol
Ther.1989;45(5):562–567.
100.LimKS,ChoJY,JangIJ,etal.Pharmacokinetic
interactionofflecainideandparoxetinein
relationtotheCYP2D6*10alleleinhealthy
Koreansubjects.BrJClinPharmacol.
2008;66(5):660–666.
101.DokiK,HommaM,KugaK,etal.Effectof
CYP2D6genotypeonflecainide
pharmacokineticsinJapanesepatientswith
supraventriculartachyarrhythmia.EurJClin
Pharmacol.2006;62(11):919–926.
102.Funck-BrentanoC,BecquemontL,Kroemer
HK,etal.Variabledispositionkineticsand
electrocardiographiceffectsofflecainideduring
repeateddosinginhumans:contributionof
geneticfactors,dose-dependentclearance,and
interactionwithamiodarone.ClinPharmacol
Ther.1994;55(3):256–269.
103.TennezeL,TarralE,DuclouxN,FunckBrentanoC.Pharmacokineticsand
electrocardiographiceffectsofanewcontrolledreleaseformofflecainideacetate:comparison
withthestandardformandinfluenceofthe
CYP2D6polymorphism.ClinPharmacolTher.
2002;72(2):112–122.
104.SwenJJ,NijenhuisM,deBoerA,etal.
Pharmacogenetics:frombenchtobyte–an
updateofguidelines.ClinPharmacolTher.
2011;89(5):662–673.
105.BrownJT,Abdel-RahmanSM,vanHaandelL,
etal.Singledose,CYP2D6genotype-stratified
pharmacokineticstudyofatomoxetinein
childrenwithADHD.ClinPharmacolTher.
2016;99(6):642–650.
106.VanDriestSL,WebberSA.Pharmacogenomics:
personalizingpediatrichearttransplantation.
Circulation.2015;131(5):503–512.
107.HuangW,LinYS,McConnDJ2nd,etal.
Evidenceofsignificantcontributionfrom
CYP3A5tohepaticdrugmetabolism.Drug
MetabDispos.2004;32(12):1434–1445.
108.GijsenV,MitalS,vanSchaikRH,etal.Ageand
CYP3A5genotypeaffecttacrolimusdosing
